133 related articles for article (PubMed ID: 35093636)
1. BLU-554, A selective inhibitor of FGFR4, exhibits anti-tumour activity against gastric cancer in vitro.
Zhang X; Zhang X; Han R; Wang Z; Yang Q; Huang Y; Yan Y
Biochem Biophys Res Commun; 2022 Mar; 595():22-27. PubMed ID: 35093636
[TBL] [Abstract][Full Text] [Related]
2. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
[TBL] [Abstract][Full Text] [Related]
3. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.
Luo Y; Yang C; Lu W; Xie R; Jin C; Huang P; Wang F; McKeehan WL
J Biol Chem; 2010 Sep; 285(39):30069-78. PubMed ID: 20657013
[TBL] [Abstract][Full Text] [Related]
4. Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer.
Ye YW; Hu S; Shi YQ; Zhang XF; Zhou Y; Zhao CL; Wang GJ; Wen JG; Zong H
Oncol Rep; 2013 Dec; 30(6):2777-84. PubMed ID: 24126887
[TBL] [Abstract][Full Text] [Related]
5. Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer.
Ye Y; Jiang D; Li J; Wang M; Han C; Zhang X; Zhao C; Wen J; Kan Q
Tumour Biol; 2016 Mar; 37(3):3185-95. PubMed ID: 26432329
[TBL] [Abstract][Full Text] [Related]
6. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
[TBL] [Abstract][Full Text] [Related]
7. Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation.
Nam Y; Shin I; Kim Y; Ryu S; Kim N; Ju E; Sim T
Neoplasia; 2022 Jan; 24(1):34-49. PubMed ID: 34864570
[TBL] [Abstract][Full Text] [Related]
8. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
Pan C; Nie W; Wang J; Du J; Pan Z; Gao J; Lu Y; Che J; Zhu H; Dai H; Chen B; He Q; Dong X
Eur J Med Chem; 2021 Dec; 225():113794. PubMed ID: 34488024
[TBL] [Abstract][Full Text] [Related]
10. Magnolin Inhibits Proliferation and Invasion of Breast Cancer MDA-MB-231 Cells by Targeting the ERK1/2 Signaling Pathway.
Wang J; Zhang S; Huang K; Shi L; Zhang Q
Chem Pharm Bull (Tokyo); 2020; 68(5):421-427. PubMed ID: 32378540
[TBL] [Abstract][Full Text] [Related]
11. Role of ERK-MAPK signaling pathway in pentagastrin-regulated growth of large intestinal carcinoma.
Mao JD; Wu P; Huang JX; Wu J; Yang G
World J Gastroenterol; 2014 Sep; 20(35):12542-50. PubMed ID: 25253956
[TBL] [Abstract][Full Text] [Related]
12. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.
Ho HK; Németh G; Ng YR; Pang E; Szántai-Kis C; Zsákai L; Breza N; Greff Z; Horváth Z; Pató J; Szabadkai I; Szokol B; Baska F; Őrfî L; Ullrich A; Kéri G; Chua BT
Curr Med Chem; 2013; 20(10):1203-17. PubMed ID: 23409720
[TBL] [Abstract][Full Text] [Related]
13. Sustained ERK activation-mediated proliferation inhibition of farrerol on human gastric carcinoma cell line by G0/G1-phase cell-cycle arrest.
Liu E; Li J; Shi S; Wang X; Liang T; Wu B; Li Q
Eur J Cancer Prev; 2016 Nov; 25(6):490-9. PubMed ID: 26656929
[TBL] [Abstract][Full Text] [Related]
14. The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer.
Li J; Ye Y; Wang M; Lu L; Han C; Zhou Y; Zhang J; Yu Z; Zhang X; Zhao C; Wen J; Kan Q
Tumour Biol; 2016 May; 37(5):6881-91. PubMed ID: 26662569
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells.
Park JM; Xian XS; Choi MG; Park H; Cho YK; Lee IS; Kim SW; Chung IS
J Cell Biochem; 2011 Apr; 112(4):1192-205. PubMed ID: 21312237
[TBL] [Abstract][Full Text] [Related]
16. Phloretin flavonoid exhibits selective antiproliferative activity in doxorubicin-resistant gastric cancer cells by inducing autophagy, inhibiting cell migration and invasion, cell cycle arrest and targeting ERK1/2 MAP pathway.
You Q; Xu J; Zhu Z; Hu Z; Cai Q
J BUON; 2020; 25(1):308-313. PubMed ID: 32277647
[TBL] [Abstract][Full Text] [Related]
17. Suppression of A549 cell proliferation and metastasis by calycosin via inhibition of the PKC‑α/ERK1/2 pathway: An in vitro investigation.
Cheng XD; Gu JF; Yuan JR; Feng L; Jia XB
Mol Med Rep; 2015 Dec; 12(6):7992-8002. PubMed ID: 26498639
[TBL] [Abstract][Full Text] [Related]
18. Flavopereirine induces cell cycle arrest and apoptosis via the AKT/p38 MAPK/ERK1/2 signaling pathway in human breast cancer cells.
Yeh HT; Tsai YS; Chen MS; Li YZ; Lin WC; Lee YR; Tseng YS; Sheu SM
Eur J Pharmacol; 2019 Nov; 863():172658. PubMed ID: 31518562
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554).
Li W; Sparidans R; El-Lari M; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Int J Pharm; 2020 Jan; 573():118842. PubMed ID: 31759109
[TBL] [Abstract][Full Text] [Related]
20. TGF-β1 Promotes Hepatocellular Carcinoma Invasion and Metastasis via ERK Pathway-Mediated FGFR4 Expression.
Huang J; Qiu M; Wan L; Wang G; Huang T; Chen Z; Jiang S; Li X; Xie L; Cai L
Cell Physiol Biochem; 2018; 45(4):1690-1699. PubMed ID: 29490293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
